MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study

MS Relapses During COVID-19 Pandemic

NCT04858763 ·Status: COMPLETED

COVID-19 and Multiple Sclerosis Disease Modifying Therapies

NCT04863586 ·Status: UNKNOWN

The MS-LINK™ Outcomes Study

NCT04735406 ·Status: COMPLETED

Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care

NCT07280871 ·Status: NOT_YET_RECRUITING

Next-Gen MS: Feed-forward PRO Data for MS Research

NCT04907305 ·Status: TERMINATED

COVID-19 Vaccine Biomarker Study in Multiple Sclerosis

NCT05121662 ·Status: COMPLETED

Covid-19 Vaccine Immune Response in Multiple Sclerosis

NCT05269888 ·Status: ACTIVE_NOT_RECRUITING

A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis

NCT01539395 ·Status: WITHDRAWN

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis

NCT01051349 ·Status: COMPLETED ·Phase: PHASE2

Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery

NCT02283918 ·Status: COMPLETED

Digitalization of Neurofunctional Tests Via a Mobile Application DAMS for Multiple Sclerosis Patients

NCT03148938 ·Status: COMPLETED ·Phase: NA

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis

NCT00870740 ·Status: COMPLETED ·Phase: PHASE2

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

NCT06735248 ·Status: RECRUITING ·Phase: PHASE2

Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis

NCT04518657 ·Status: RECRUITING ·Phase: NA

Impact of the Modifications of Environmental Exposures and Health Care Access During COVID-19 Lockdown on Multiple Sclerosis

NCT05033782 ·Status: COMPLETED

Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis

NCT04834401 ·Status: COMPLETED

Protection Against Severe Coronavirus Disease 2019 in Patients With Multiple Sclerosis Stratified According to Disease Modifying Treatment

NCT05834335 ·Status: COMPLETED

Genes and Environment in Multiple Sclerosis

NCT01353547 ·Status: RECRUITING

CorEvitas Multiple Sclerosis (MS) Registry

NCT03291756 ·Status: ENROLLING_BY_INVITATION

Assessment of Patient Use of a New Device: RebiSmart

NCT01195870 ·Status: COMPLETED

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)

NCT01405820 ·Status: COMPLETED ·Phase: PHASE2

A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT01808482 ·Status: TERMINATED ·Phase: PHASE1

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

NCT01601119 ·Status: COMPLETED

Adherence Trial With MS LifeLines ® Services

NCT01905527 ·Status: TERMINATED

The United Kingdom Multiple Sclerosis Register Covid-19 Substudy

NCT04354519 ·Status: UNKNOWN